This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levy, S. A.
Right arrow Articles by DiMarco, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, S. A.
Right arrow Articles by DiMarco, A. A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, January 2008, p. 115-119, Vol. 15, No. 1
1071-412X/08/$08.00+0     doi:10.1128/CVI.00340-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Quantitative Measurement of C6 Antibody following Antibiotic Treatment of Borrelia burgdorferi Antibody-Positive Nonclinical Dogs{triangledown}

Steven A. Levy,1 Thomas P. O'Connor,2* Jancy L. Hanscom,2 Paulette Shields,2 Leif Lorentzen,3 and Anthony A. DiMarco2

Durham Veterinary Hospital PC, 178 Parmelee Hill Road, Durham, Connecticut 06422,1 Dept. of Research and Development,2 Dept. of Marketing, IDEXX Laboratories, Inc., Westbrook, Maine 040923

Received 16 August 2007/ Returned for modification 6 September 2007/ Accepted 7 November 2007

The detection of antibody to the Borrelia burgdorferi C6 peptide by use of enzyme-linked immunoassays is a widely accepted method for the diagnosis of Lyme disease spirochete infection in dogs and in humans. Antibody to the C6 peptide is highly specific for B. burgdorferi and declines following treatment of dogs and humans exposed to B. burgdorferi. A quantitative assay for determining C6 antibody levels was developed and used to measure changes in antibody levels following antibiotic treatment of B. burgdorferi antibody-positive nonclinical dogs. One hundred thirty-two client-owned dogs were used in the study; 64 were negative, 53 of 68 positive animals received treatment, and 15 were untreated controls. Test sera were collected at 3, 6, and 12 months from seropositive dogs receiving treatment and untreated controls. Dogs in the treated group were assigned to moderate-to-high (≥29 U/ml)- and low (<29 U/ml)-C6-level groups because the change in the C6 level after treatment was dependent on the level prior to treatment. There were significant declines in the 30 dogs with moderate-to-high initial C6 levels that exceeded the maximal declines of the untreated control dogs in all cases at 6 months (16 data points) and 12 months (29 data points) posttreatment. There was little change in C6 level following antibiotic therapy in the 23 dogs with low initial C6 levels. The quantitative C6 antibody test can be used to measure changes in C6 antibody levels following treatment of antibody-positive nonclinical dogs.


* Corresponding author. Mailing address: Dept. of Research and Development, IDEXX Laboratories, Inc., Westbrook, ME 04092. Phone: (207) 556-4428. Fax: (207) 556-8969. E-mail: tom-oconnor{at}IDEXX.com

{triangledown} Published ahead of print on 14 November 2007.


Clinical and Vaccine Immunology, January 2008, p. 115-119, Vol. 15, No. 1
1071-412X/08/$08.00+0     doi:10.1128/CVI.00340-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Krupka, I., Knauer, J., Lorentzen, L., O'Connor, T. P., Saucier, J., Straubinger, R. K. (2009). Borrelia burgdorferi Sensu Lato Species in Europe Induce Diverse Immune Responses against C6 Peptides in Infected Mice. CVI 16: 1546-1562 [Abstract] [Full Text]